https://www.selleckchem.com/pr....oducts/dapansutrile.
Real-world data on prophylaxis of severe haemophilia A (HA) patients treated by emicizumab are scarce. To study the efficacy and safety of longitudinal emicizumab prophylaxis and assess laboratory monitoring correlations in a large patient cohort. HA patients with and without FVIII inhibitors, initiating emicizumab prophylaxis, were prospectively enrolled. Bleeding, adverse events and surgeries were documented. FVIII inhibitors, emicizumab levels and thrombin generation (TG) were sequentially measured. A total of 107 patients, incl
Suka
Komentar
Membagikan
